Learn to edit and create professional-looking videos with minimal effort
Article content
Entrepreneurs often need to create high-quality video content for marketing, training or client engagement, but may not have the time or resources for a full video production team. However, recent AI improvements have made it possible to automate much of the creative process. With the right tools, business owners can now produce professional, on-brand content from their desktops without relying on outside editors or design teams.
Article content
Article content
Canvid is an AI-powered video creation and screen recording platform that simplifies this process. Designed for business users, it enables the production of polished tutorials, product demos and presentations using built-in automation and intelligent editing tools. For entrepreneurs balancing content creation with other day-to-day responsibilities, Canvid helps reduce production time while maintaining a high standard of visual quality.
Article content
Available for both Windows and Mac, Canvid offers a suite of intelligent features including one-click screen recording, automatic zoom, motion effects and real-time voice enhancement. These tools are particularly useful for explaining digital workflows, showcasing software or creating professional training materials.
Article content
Users can also take advantage of built-in auto-captioning, customizable layouts and webcam background removal, which help produce content that looks branded and consistent, even in less-than-ideal recording environments.
Article content
Canvid is a one-time purchase that includes lifetime access to the core software and unlimited video exports. Users can record in up to 4K resolution and work across three devices. The purchase also includes two years of product updates and 50GB of cloud storage. After this period, cloud access can be renewed, but the core recording and editing features remain fully functional without additional payment.
Article content
Article content
For business owners seeking a cost-effective solution for video creation, Canvid presents a practical option. It eliminates the complexity of traditional editing software while offering the functionality needed to produce clear, professional content.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 minutes ago
- Globe and Mail
Gene Therapy Competitive Landscape Report 2025
DelveInsight's, ' Gene Therapy Competitive landscape, 2025,' report provides comprehensive insights about 180+ companies and 200+ drugs in Gene Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Gene Therapy Treatment Landscape @ Gene Therapy Pipeline Outlook Key Takeaways from the Gene Therapy Competitive Landscape Report On 17 August 2025, MeiraGTx LLC conducted a study of individual participation in this study will be approximately 54 months for participants who received AAV-GAD in Study MGT-GAD-025 and approximately 60 months for participants who received sham surgery in Study MGT-GAD-025. On 15 August 2025, Janssen Research & Development LLC organized a Phase 3 Follow-up Study of for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene. On 13 August 2025, REGENXBIO Inc. announced a phase I/II/III study to evaluate the safety, tolerability, pharmacodynamics (microdystrophin protein levels), pharmacokinetic, and clinical efficacy of RGX-202 when administered IV as one-time dose to ambulant male participants with Duchenne. A comprehensive, short-term, prophylactic immunosuppression regimen will be administered during treatment to mitigate a potential immune response. This study is being conducted in three sequential parts: a phase I/II study (Part 1), a phase 3 pivotal study (Part 2) and a confirmatory study (Part 3). Part 1 will study a one-time dose of RGX-202 (1x10^14 or 2x10^14 GC/kg) in up to 15 participants with Duchenne. DelveInsight's Gene Therapy Competitive landscape report depicts a robust space with 180-+ active players working to develop 200+ pipeline therapies for Gene Therapy treatment. The leading Gene Therapy Companies such as Pfizer, Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, Adverum Biotechnologies, Kyverna Therapeutics, Vivet Therapeutics, HELIXMITH Co, Rocket Pharmaceuticals, Bristol-Myers Squibb, Wellington Zhaotai Therapies, Reyon Pharmaceutical, Neowise Biotechnology, Orna Therapeutics, Genflow Biosciences, Xylocor Therapeutics, Kolon TissueGene, Allogene Therapeutics, Nanjing IASO Biotherapeutics, Shanghai Vitalgen BioPharma, Rui Therapeutics, Obsidian Therapeutics, YolTech Therapeutics, Neurotech USA, Beacon Therapeutics, REGENXBIO and others. Promising Gene Therapy Therapies such as Tipifarnib, Sucrose (3%), Chemotherapy, UX111, SPK-8011, SBT101, Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib and others. Discover groundbreaking developments in Gene Therapy Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Gene Therapy Clinical Trials Assessment Gene Therapy Marketed Therapies Novartis Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, company use innovative science and digital technologies to create transformative treatments in areas of great medical need. In quest to find new medicines, consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and are finding innovative ways to expand access to company latest treatments. Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, company is working to turn promising gene therapies into proven treatments. Zolgensma Zolgensma (onasemnogene abeparvovec) is the only gene therapy for spinal muscular atrophy (SMA) and the only SMA treatment designed to directly address the genetic root cause of the disease by replacing the function of the missing or non-working SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time IV infusion. Zolgensma was approved by the US Food and Drug Administration for the treatment of pediatric patients less than 2years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. . Zolgensma is now approved in more than 40 countries and more than 2,000 patients have been treated with Zolgensma globally across clinical trials, managed access programs, and in the commercial setting. Spark Therapeutics Spark Therapeutics, is a fully integrated company committed to discovering, developing and delivering gene therapies, challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. The company have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, there is the path to a world where no life is limited by genetic disease. LUXTURNA LUXTURNA is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease (IRD) and the first adeno-associated virus (AAV) vector gene therapy approved in the U.S. LUXTURNA was approved by FDA under Priority Review and previously received orphan drug and breakthrough therapy designations from FDA. With the approval of LUXTURNA, FDA will issue to Spark Therapeutics a Rare Pediatric Disease Priority Review Voucher for a Priority Review of a subsequent marketing application for a different product. Spark Therapeutics' Marketing Authorization Application (MAA) for LUXTURNA is currently under review with the European Medicines Agency (EMA). LUXTURNA also has received orphan product designations from EMA. Gene Therapy Pipeline Therapies Pfizer Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849 when it was founded by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company is engaged in the discovery, development, manufacture, and sale of medicines and vaccines across various therapeutic areas such as vaccines, oncology, internal medicine, hospital, inflammation and immunology, and rare diseases. Pfizer's dedication to global health is evident through its extensive portfolio of medicines and vaccines that aim to enhance wellness, prevention, treatments, and cures for various diseases. The company collaborates with healthcare providers, governments, and communities worldwide to expand access to reliable and affordable healthcare services. Fordadistrogene movaparvovec Fordadistrogene movaparvovec is an investigational recombinant adeno-associated virus serotype 9 (AAV9) capsid carrying a shortened version of the human dystrophin gene (mini-dystrophin) under the control of a human muscle-specific promotor. The AAV9 capsid was chosen as the delivery mechanism because of its potential to target muscle tissue. The FDA has lifted a clinical hold on Pfizer's phase III clinical trial of its investigational gene therapy, fordadistrogene movaparvovec, in patients with Duchenne muscular dystrophy (DMD). Regulatory and ethics approvals to resume the CIFFREO Phase III ambulatory study, including the FDA's lift of its clinical hold, follow reviews of data and protocol amendments. Currently the drug is in Phase III stage of development for the treatment of Duchenne muscular dystrophy Ultragenyx Pharmaceutical Inc Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, the company apply cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – The company focus on purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. DTX401 DTX401 is an investigational AAV8 gene therapy designed to deliver stable expression and activity of G6Pase-α using a single intravenous infusion. Long term Phase I/II data demonstrate an acceptable safety profile and durability of response. All treated patients have experienced stable or improved glucose control while tapering or discontinuing oral glucose replacement therapy with cornstarch after receiving DTX401. The Phase III GlucoGene study is underway to evaluate the ability of DTX401 to reduce the use of cornstarch while maintaining or improving glucose control as well as the therapy's impact on patients' quality of life. DTX401 was granted Orphan Drug Designation in the United States, EU and United Kingdom, and Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation in the United States. DTX401 was accepted into the EMA's Priority Medicines program (PRIME), enabling more frequent interactions with the EMA and the potential for an accelerated drug has recently completed Phase III clinical trial for the treatment of patients with Glycogen storage disease type I. Rocket Pharmaceuticals Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket's multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket's first AAV-based gene therapy program targets Danon disease, a rare neuromuscular and cardiovascular disease. RP-L102 RP-L102 is a gene therapy product containing autologous (patient-derived) hematopoietic stem cells (HSCs) that have been genetically modified with a lentiviral vector to contain a functional copy of the FANCA gene. If given early in life, RP-L102 gene therapy has the potential to serve as a preventative measure, correcting bone marrow cells before there is progression to severe bone marrow failure. RP-L102 has been granted Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations for the treatment of Fanconi Anemia type A in the United States and Orphan Drug designation in Europe. The drug is currently in Phase II stage of development for the treatment of patients with Fanconi Anemia (FA). Adverum Biotechnologies Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with neovascular or wet age-related macular degeneration. ADVM-022 ADVM022 is being developed for the treatment of wet AMD. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach) ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD. The OPTIC trial is designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. The drug is currently in Phase II stage of development for the treatment of patients with Wet AMD. Kyverna Therapeutics Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including two ongoing multi-center, open-label Phase I trials of KYV-101 in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. By advancing more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated. KYV-101 KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase I trial in oncology. Results were published by the NIH in Nature Medicine. Kyverna is currently conducting trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additional clinical trials of KYV-101 in systemic sclerosis, and myasthenia gravis are in preparation. The drug is currently in Phase I/II stage of development for the treatment of patients with Lupus nephritis. Vivet Therapeutics Vivet Therapeutics is a private, clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic conditions, including Wilson's disease. Vivet's gene therapy platform uses recombinant adeno-associated viruses (rAAVs) as vectors and has initiated two clinical programs and four pre-clinical assets to date. Its most advanced therapy is VTX-801, a novel gene therapy for Wilson's disease, with key clinical read-outs expected by the end of 2024. Vivet Therapeutics was founded in 2016 by CEO Dr Jean-Philippe Combal and CSO Dr Gloria Gonzalez-Aseguinolaza and is led by a highly experienced management team with deep expertise developing gene therapies and orphan drugs. VTX-802 VTX-802 is an AAV-based gene therapy for patients with Progressive Familial Intrahepatic Cholestasis Type 2. It delivers a codon-optimized version of the BSEP gene to the liver and is currently under preclinical testing. The drug is currently in Preclinical stage of development for the treatment of patients with Intrahepatic cholestasis. Gene Therapy Analytical Perspective by DelveInsight In-depth Commercial Assessment: Gene Therapy Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Gene Therapy Competitive Landscape The report comprises of comparative assessment of Companies (by therapy, development stage, and technology). Gene Therapy Report Assessment Company Analysis Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Transform your understanding of the Gene Therapy Pipeline! See the latest progress in drug development and clinical research @ Gene Therapy Market Drivers and Barriers, and Future Perspectives Scope of the Gene Therapy Competitive Landscape Report Coverage- Global Gene Therapy Companies- Pfizer, Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, Adverum Biotechnologies, Kyverna Therapeutics, Vivet Therapeutics, HELIXMITH Co, Rocket Pharmaceuticals, Bristol-Myers Squibb, Wellington Zhaotai Therapies, Reyon Pharmaceutical, Neowise Biotechnology, Orna Therapeutics, Genflow Biosciences, Xylocor Therapeutics, Kolon TissueGene, Allogene Therapeutics, Nanjing IASO Biotherapeutics, Shanghai Vitalgen BioPharma, Rui Therapeutics, Obsidian Therapeutics, YolTech Therapeutics, Neurotech USA, Beacon Therapeutics, REGENXBIO and others. Gene Therapy Analytical Perspective: In-depth Commercial Assessment Gene Therapy Unmet Needs, Preclinical and Discovery Stage Products Stay Ahead in Oncology Research–Access the Full Gene Therapy Pipeline Analysis Today! @ Gene Therapy Drugs and Companies Table of Contents Introduction Executive Summary Gene Therapy: Overview Gene Therapy -Analytical Perspective: In-depth Commercial Assessment Competitive Landscape Therapeutic Assessment Gene Therapy: Company and Product Profiles (Marketed Therapies) Novartis Zolgensma Gene Therapy: Company and Product Profiles (Pipeline Therapies) Late Stage Products (Phase III) Pfizer Fordadistrogene movaparvovec Mid Stage Products (Phase II) Rocket Pharmaceuticals RP-L102 Early Stage Products (Phase I/II) Kyverna Therapeutics KYV-101 Preclinical and Discovery Stage Products Vivet Therapeutics VTX-802 Inactive Products Gene Therapy- Unmet needs Gene Therapy – Market drivers and barriers Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
6 minutes ago
- Globe and Mail
Why Did Uranium Energy Stock Crash Today?
Key Points Uranium spot prices are on the rise again after a sharp turn lower in June. Uranium Energy stock dropped on no significant news today. The uranium mining stock is unprofitable and subject to sharp changes in sentiment, with or without news behind them. 10 stocks we like better than Uranium Energy › Uranium Energy (NYSEMKT: UEC) stock tumbled 10.5% through 2:20 p.m. ET Tuesday on no obvious bad news. Actually, the opposite is true: the latest news for uranium stocks (and presumably for Uranium Energy stock) looks pretty good. According to "uranium prices and nuclear equities are surging as tight supply, underbuilt production pipelines, and policy-driven nuclear revival create a structural supply deficit." All of this means uranium prices -- and uranium stocks, too -- should be going higher. Uranium prices remain strong Indeed, uranium prices already are going higher. Since hitting a recent high near $80 back in June, uranium prices per pound dropped in July, but then resumed growing. At last report, the atomic fuel's price had passed $73. Of course, this may be part of the problem. The spot market price of mined uranium is common knowledge, as is President Trump's support for the nuclear industry in the U.S. All of this contributes to price strength in uranium. It's also helped drive up the share price of Uranium Energy stock more than 100% over the past year. Is Uranium Energy stock a buy? And why is this a problem? Not to put too fine a point on it, it's a problem because Uranium Energy stock isn't currently profitable to support its higher stock price. To the contrary, losses of $0.07 per share are expected to more than double to $0.18 this year, and analysts polled by S&P Global Market Intelligence don't think Uranium Energy stock will turn profitable again before 2027 at the earliest. Until Uranium Energy begins producing consistent profits, investors should expect its stock to remain volatile, going up or down abruptly on good and bad news -- and sometimes on no news at all. Should you invest $1,000 in Uranium Energy right now? Before you buy stock in Uranium Energy, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Uranium Energy wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,076% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025
Globe and Mail
6 minutes ago
- Globe and Mail
Comcast to Participate in Goldman Sachs Investor Conference
Comcast Corporation (Nasdaq: CMCSA) announced that on Tuesday, September 9, 2025, Mike Cavanagh, President of Comcast Corporation, will participate in the Goldman Sachs Communacopia + Technology Conference. A live webcast of the event will be available on the Company's Investor Relations website at on Tuesday, September 9, 2025, at 11:10 A.M. Eastern Time. An on-demand replay will be available shortly after the conclusion of the presentation. To automatically receive Comcast financial news by e-mail, please visit and subscribe to E-mail Alerts. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit for more information.
